Keyphrases
Puberty
100%
Gonadotropin-releasing Hormone
100%
Childhood Diseases
100%
Precocious Puberty
100%
Pediatric Patients
22%
Adult Height
22%
Agonist Treatment
16%
Combination Therapy
11%
Bone Mineral Density
11%
Enhanced Growth
11%
Gonadal Function
11%
Growth Hormone Deficiency
11%
Cytotoxic Therapy
11%
Gonadotropin-releasing Hormone Antagonist
11%
Body Mass Index
5%
Growth Rate
5%
Growth Hormone
5%
Body Composition
5%
Small-for-gestational Age
5%
Reproductive Function
5%
Negative Effects
5%
Adverse Effects
5%
Congenital Adrenal Hyperplasia
5%
Malignancy
5%
Gonadotropins
5%
Linear Growth
5%
Combined Therapy
5%
Reproductive Potential
5%
Reproductive Endocrine
5%
Receptor Activity
5%
Genetic Potential
5%
Gonadotropin-releasing Hormone Receptor (GnRHR)
5%
Renal Transplant Recipients
5%
Primary Hypothyroidism
5%
Growth Benefits
5%
Therapy Discontinuation
5%
Endocrine Physiology
5%
Pediatric Kidney Transplantation
5%
Skeletal Age
5%
Skeletal Maturation
5%
Medicine and Dentistry
Gonadorelin Agonist
100%
Disease
100%
Precocious Puberty
100%
Pediatrics Patient
36%
Human Growth Hormone
36%
Combination Therapy
18%
Bone Density
18%
Cytotoxic Chemotherapy
18%
Growth Hormone Deficiency
18%
Gonad Function
18%
Pediatrics
9%
Body Mass Index
9%
Bone Maturation
9%
Kidney Graft
9%
Small for Gestational Age
9%
Cancer
9%
Growth Hormone
9%
Hypothyroidism
9%
Bone Age
9%
Gonadotropin Release
9%
Endocrine Function
9%
Combined Therapy
9%
Congenital Adrenal Hyperplasia
9%
Adverse Effect
9%
Reproductive Medicine
9%
Gonadorelin Receptor
9%
Pharmacology, Toxicology and Pharmaceutical Science
Gonadorelin Agonist
100%
Gonadorelin Derivative
100%
Precocious Puberty
100%
Human Growth Hormone
36%
Combination Therapy
18%
Cytotoxic Chemotherapy
18%
Gonadorelin Antagonist
18%
Growth Hormone Deficiency
18%
Growth Hormone
9%
Small for Date Infant
9%
Gonadotropin
9%
Short Stature
9%
Hypothyroidism
9%
Congenital Adrenal Hyperplasia
9%
Gonadorelin Receptor
9%